Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2025 | $3.00 | Buy | H.C. Wainwright |
H.C. Wainwright initiated coverage of Virax Biolabs Group Ltd. with a rating of Buy and set a new price target of $3.00
Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.LONDON, Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement of its securities for total gross proceed
LONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the purchase and sale of 12,500,000 ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares at a purchase price of $0.40 per ordinary share and associated preferred investment option in a private placement . The prefer
Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series of recent clinical and operational milestones over the past 12 months. LONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors.
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
LONDON, July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025. Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable service and contributions. Dr. Miller brings over 30 years of leadership expe
LONDON, Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO"). Dr. McCracken will succeed Mr. Cameron Shaw, who is moving to Virax's Advisory Board, and will lead the Company's various growth initiatives, including the Company's expected near-term research-use-only launch of ViraxImmune™. "We are excited to welcome Dr.
LONDON, Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales. "We are thrilled to welcome Richard to our team," said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs. "Richard brings almost 25 years of experience in successfully commercializing novel and disruptive technological products in the research, routine
SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)
SC 13G - Virax Biolabs Group Ltd (0001885827) (Subject)